Arcturus Therapeutics Holdings (ARCT) EBIT Margin (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported EBIT Margin of 1403.74% for Q1 2026, down 134647.0% on a YoY basis from N/an in Q1 2025, and down 222.65% quarter-over-quarter from 435.06% in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) EBIT Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported EBIT Margin for 9 years, with the latest figure at 1403.74% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 134647.0% year-over-year to 1403.74%; the trailing twelve-month figure through Mar 2026 stood at 161.52% (down 10439.0% YoY), and the FY2025 full-year result was 92.96%, down 3015.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 1403.74%, down from 435.06% in the prior quarter.
- The five-year high for EBIT Margin was 75.77% in Q4 2022, with the low at 1403.74% in Q1 2026.
- Historically, EBIT Margin has averaged 245.88% across 5 years, with a median of 80.01% in 2024.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 260313 bps — and 2026, when it tumbled 134647 bps.
- Arcturus Therapeutics Holdings' EBIT Margin stood at 75.77% in 2022, then sank by 178 bps to 59.22% in 2023, then tumbled by 148 bps to 146.68% in 2024, then slumped by 197 bps to 435.06% in 2025, then sank by 223 bps to 1403.74% in 2026.
- The last three EBIT Margin figures came in at 1403.74% (Q1 2026), 435.06% (Q4 2025), and 96.27% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | -1,403.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,403.74% |
| Dec 31, 2025 | -435.06% |
| Sep 30, 2025 | -96.27% |
| Jun 30, 2025 | -41.04% |
| Mar 31, 2025 | -57.27% |
| Dec 31, 2024 | -146.68% |
| Sep 30, 2024 | -25.76% |
| Jun 30, 2024 | -42.37% |
| Mar 31, 2024 | -80.01% |
| Dec 31, 2023 | -59.22% |
| Sep 30, 2023 | -42.79% |
| Jun 30, 2023 | -526.42% |
| Mar 31, 2023 | 18.38% |
| Dec 31, 2022 | 75.77% |
| Sep 30, 2022 | -275.32% |
| Jun 30, 2022 | -81.53% |
| Mar 31, 2022 | -960.70% |
| Dec 31, 2021 | -649.72% |
| Sep 30, 2021 | -2,208.49% |
| Jun 30, 2021 | -2,684.66% |